Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Inapsine, Droleptan, Xomolix, Innovar
Droperidol is a butyrophenone antipsychotic with sedative and antiemetic properties. It acts primarily as a dopamine D2 receptor antagonist, but also has some activity at other receptors. It is used for the short-term treatment of agitation, postoperative nausea and vomiting, and as a pre-operative medication.
For short-term treatment of agitation, postoperative nausea and vomiting, and as a pre-operative medication.
Droperidol may prolong the QT interval, increasing the risk of torsades de pointes, a potentially fatal ventricular arrhythmia. Electrocardiographic monitoring is recommended, especially in patients with risk factors for QT prolongation.
Outcome:
Increased risk of torsades de pointes
Mechanism:
Additive QT prolongation
Outcome:
Increased sedation
Mechanism:
Additive CNS depression
Outcome:
Reduced sedative effects of droperidol
Mechanism:
Caffeine's stimulant effects
Most likely new formulation: Extended-release injectable formulation (Year: 2026, 30% confidence)
Based on current usage trends and safety profile, there is a low probability (<5%) of droperidol being withdrawn from the market in the next 5 years.
Antipsychotic, Antiemetic
Butyrophenone